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Abstract:    19 
 20 
Although genetic modification is still a subject of discussion, both in political and research forums, the widespread 21 
adoption of biofortified food crops in China is likely to happen. In the scope of biofortification for improving human 22 
nutrition, folate biofortified rice was recently developed as a remedy against folate deficiency and its adverse health 23 
outcomes, among which neural-tube defects (NTDs). The objective of this paper is to analyze the potential health 24 
benefits of folate enriched rice in China, a rice consuming country characterized by large folate deficiencies. The 25 
Disability-Adjusted Life Years (DALY) method is used to calculate the impact of biofortification as the number of 26 
DALYs saved due to the reduced number of NTDs. A low and high impact scenario are simulated according to the 27 
coverage rate of folate enriched rice consumption. Our findings support folate biofortification of rice as a valuable 28 
alternative to increase folate intake and reduce folate deficiency in China. Implementing rice with a folate content of 29 
1,200 µg per 100 g rice in China would increase the total daily folate intake for Chinese women of childbearing age to 30 
1,120 µg, which is almost three times the recommended folate intake. As a consequence, around 116,090 DALYs in the 31 
low impact scenario and 257,345 DALYs in the high impact scenario would be saved by implementing biofortified rice. 32 
Although rice consumption is lower in northern areas, these regions account for the biggest health impact of 33 
biofortification in China. As expected, regions with high NTD prevalence rates, such as Shanxi Province, will benefit 34 
most from folate biofortification of rice. Further research is needed to assess the cost-effectiveness of this intervention 35 
and to compare different interventions to increase folate intake, such as a campaign to promote folic acid pills intake. 36 
Especially in poor, rural regions where other folate interventions are often unsuccessful, folate enriched rice could be an 37 
effective, complementary approach to combat folate deficiency. 38 
 39 
Key words: Folate biofortified rice; folate deficiency, neural-tube defects; health impact; DALYs; 40 
China. 41 
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1. Introduction 112 
 113 
Micronutrient malnutrition is a major health problem, affecting more than half of the world 114 
population, especially in developing countries. Biofortification, enhancing the micronutrient content 115 
of staple food crops, is considered as an excellent alternative to other micronutrient interventions, 116 
such as supplementation, industrial fortification and diet diversification. In 2007, Storozhenko et al
1
 117 
developed rice with a high folate content as an alternative means to tackle folate deficiency. Folate 118 
deficiency, characterized by a below normal folate intake (< 400 µg per day), is an important type 119 
of micronutrient deficiency that is associated with an increased risk of diseases, such as neural-tube 120 
defects (NTD), which is the most common congenital malformation in the world
2
. The relationship 121 
between folate deficiency and its main adverse health outcome, NTDs, is well established in 122 
scientific literature
3-5
. Periconceptional folate intake reduces the risk of delivering a baby with an 123 
NTD.  124 
Although not yet available on the market, previous research on folate biofortified rice 125 
explored consumers‟ acceptance and purchase intention in Shanxi Province6. The selection of this 126 
poor region in Northern China was based on its relation with NTDs and folate deficiency. Shanxi 127 
has one of the highest reported prevalence rates of NTDs in the world, with more than 60 NTDs per 128 
10,000 births
7-9
. Furthermore, strongly related to this high NTD risk, this region is characterized by 129 
a low intake of folic acid pills
10-12
 and dietary folate
13
. Expanding this study location to China as a 130 
whole would improve the evaluation of folate biofortified rice for two reasons. First of all, China is 131 
not only the world leader in the production and consumption of this staple crop, it is also considered 132 
as one of the pioneers of R&D and commercialization of genetically modified (GM) foods and, in 133 
particular, rice
14, 15
. Recently, China‟s Ministry of Agriculture (MOA) granted two bio-safety 134 
certificates and approved biotech Bt rice and phytase maize
16
. The permission to cultivate these 135 
important transgenic crops will lead to its large-scale production in about two to three years. 136 
Second, China as a rice consuming country is characterized by large folate deficiencies and high 137 
NTD prevalence rates
17
, which makes rice an appropriate food vehicle for folate biofortification. 138 
Although there are significant differences in rice consumption and folate status between the 139 
northern and southern regions, a regional comparison of the health impact would further underpin 140 
the ex-ante evaluation of the health impact of folate biofortification in China.  141 
Biofortification of the world‟s major staple crop is expected to have a large impact on folate 142 
related health problems. This paper is the first attempt to quantify the potential health benefits of a 143 
folate biofortified crop. Based on the Disability-Adjusted Life Year (DALY) framework
18
, the 144 
health impact is measured in terms of “healthy” life years saved due to biofortification. Although 145 
the DALY framework has been criticized in the past
19, 20
, it is increasingly used as a method in 146 
health impact studies of biofortified staple crops
21-24
. Previous impact studies evaluated the health 147 
effect of biofortified crops, such as Golden Rice
25, 26
 or other provitamin A enriched crops such as 148 
cassava roots
27
 or sweet potatoes
24
, or iron fortified beans
28
, on main micronutrient deficiencies (i.e. 149 
iron, zinc or vitamin A) in developing countries like Bangladesh, Philippines, Nigeria or India. This 150 
study focuses on the introduction of folate biofortified rice in China, which is a relatively new area 151 
to evaluate biofortified staple crops
24, 29
, and investigates the differences in the health impact 152 
between northern and southern regions.  153 
 154 
Figure 1 gives a brief overview of the application of the DALY framework to determine the 155 
health impact of the potential introduction of folate biofortified rice in China. The main concepts in 156 
this figure are elaborated in the next sections. 157 
 158 
 159 
 160 
 161 
 162 
 163 
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 176 
Figure 1 Application of the DALY approach to measure the health benefits of folate biofortified rice in disability-177 
adjusted life years  178 
 179 
Section 2 and 3 focus on folate deficiency and NTDs, respectively. Besides a general 180 
description, these sections present the status of folate deficiency and NTDs in the world and, in 181 
particular, in China. In section 4, the current burden of folate deficiency in China is estimated by 182 
means of the DALY formula. With respect to the theoretical background of this applied method, 183 
reference is made to the “Fourth HarvestPlus Technical Monograph”23. The fifth section gives an 184 
overview of the policy interventions to tackle folate deficiency, with specific attention to the 185 
Chinese (policy) context. The sixth section assesses the potential reduction of the current burden of 186 
folate deficiency due to the implementation of folate enriched rice, i.e. the health impact. Finally, 187 
some conclusions are drawn and recommendations for future research are presented. 188 
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2. Folate deficiency 191 
 192 
 193 
Nutritional deficiency of folate or folate deficiency is characterized by an inadequate intake 194 
of folate, i.e. below 400 µg per person, per day. This is the daily recommended dose, as advised by 195 
the World Health Organization (WHO)
30
 and the US Public Health Service
31
. Suboptimal folate 196 
intake may result in the onset of diseases and disorders, such as neural-tube defects (NTD), 197 
megaloblastic anemia and aggravation of iron deficiency anemia
32, 33
. In addition, albeit that a 198 
causal link still needs to be proven, folate deficiency has been correlated with certain types of 199 
cancer, such as leukemia, colorectal, breast, cervical, pancreatic and bronchial cancer, Alzheimer‟s, 200 
coronary and cardiovascular diseases
2
. These disorders can be broadly divided into three groups of 201 
causes, homocysteinemia, hypomethylation and an errant DNA biosynthesis
33
, and can be prevented 202 
by an adequate folate intake
5, 34
.  203 
Folate is water-soluble vitamin, found in a wide variety of foods. The most important dietary 204 
folate sources are green and/or leafy vegetables (e.g. beans, peas and spinach), eggs, liver and 205 
certain fruits (e.g. citrus fruits and oranges)
35
. Potential side effects of (high) folate intake include 206 
cognitive impairment (only in combination with Vitamin B12 deficiency), facilitated progression and 207 
growth of preneoplastic lesions and subclinical cancers and impaired  immune function of 208 
postmenopausal women
36
. On the contrary, folic acid is a synthetic form of folate, which does not 209 
occur naturally, but is commercially produced into pills (supplementation) or added to foods 210 
(fortification). However, humans may be much poorer at handling folic acid than what had been 211 
previously thought and there is now more concern that circulating unmetabolised folic acid may 212 
have some downsides
37
. Compared to folate, very high intakes of folic acid (>1,000 µg/day) can 213 
mask Vitamin B12 deficiency
38
. Besides masking micronutrient deficiencies, a high folate acid 214 
intake level may also lead to other adverse health effects, such as a cognitive decline in the elderly 215 
and a higher risk for colorectal cancer (for a review on potential side effects of folate, folic acid and 216 
other micronutrients, see Rogovik et al
39
). These potential negative health outcomes of raising the 217 
folic acid status partly explain the political reluctance to proceed to mandatory folic acid 218 
fortification in Europe
40, 41
 (see section 5.1.2). 219 
 220 
2.1. Folate deficiency in the world 221 
 222 
As the most important staple foods, such as potatoes and cereals, are poor sources of 223 
folate
35
, folate deficiency is a global problem for public health. Figure 2 and figure 3 summarize the 224 
scientific evidence of the magnitude of folate deficiencies, based on the plasma folate 225 
concentrations and the folate deficiency rate, respectively. These findings are based on a worldwide 226 
review on adult folate deficiency
42
, which compared the results of the most representative survey of 227 
each reviewed country. The threshold of folate deficiency is defined by a plasma folate status below 228 
10 Nmol/L
43
, as suggested at the WHO Technical Consultation on folate and vitamin B12 229 
deficiencies in 2005
44
.  230 
In line with other micronutrient deficiencies, folate deficiency is more prevalent in less 231 
developed, non-western countries. Most of the Western countries are well above this threshold, 232 
especially after the implementation of folic acid fortification programs (see section 5). However, a 233 
high average folate status does not imply that folate deficiency is absent, as figure 3 shows.  234 
With respect to China, a regional comparison is made. If only the figures of China as a 235 
whole would be presented, the differences between Northern and Southern China would be masked. 236 
The average plasma folate concentration of Northern China is below the threshold of folate 237 
deficiency, by which the number of folate deficient adults is significantly higher than in Southern 238 
China (see section 2.2). 239 
 240 
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 241 
Figure 2 Folate deficiency in the world. Average plasma folate concentrations (in Nmol/L), per country  242 
Source: Mclean et al
42
, and Hao et al
45
 for China 243 
Remarks:  Prefortification values are presented in countries with mandatory fortification programs (Canada, Chile, Costa Rica, and the United States). 244 
The threshold of folate deficiency is defined by a plasma folate concentration below 10 Nmol/L43, 44. 245 
 246 
 247 
 248 
Figure 3 Folate deficiency in the world. Percentage of adults with folate deficiency, per country  249 
Source: Mclean et al
42
, and Hao et al
45
 for China 250 
Remarks: In countries with mandatory fortification programs, such as Costa Rica and the United States, prefortification values are presented. 251 
 252 
2.2. Folate deficiency in China 253 
 254 
Given the low folate content of China‟s main staple crop, rice, folate deficiency in China is 255 
expected to be high. However, scientific evidence on the number of folate deficient people in China 256 
is limited. Only two study reported the folate deficiency rate in Chinese regions spread across the 257 
country
17, 45
. Other folate status and intake assessment studies in China focused on specific regions, 258 
characterized by a low (Shanghai
46
, Jiangsu
12, 47
 and Anqing
48
) or high (Shanxi
12, 13, 47, 49
 and 259 
Beijng
50
) NTD prevalence rate. The target group in most of these studies was limited to Chinese 260 
women of childbearing age (CBA), premarital women or pregnant women, due to their potential 261 
risk of having a baby with an NTD caused by folate deficiency. 262 
The results of two Chinese studies, i.e. a study on folate deficiency of men and women 263 
versus the most recent study on folate status of women of childbearing age, are summarized in 264 
Table 1. The regional distribution of the number of folate deficient people, regardless of gender, 265 
indicates a significant difference between Northern and Southern China. In total, about 19.6 % or 266 
258.8 million people in China are considered to be folate deficient, of which 81.7 % is living in 267 
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Northern China. The higher number of folate deficient people in Northern China is partly 268 
attributable to the lower availability and the limited variety of fresh vegetables, and the lower 269 
consumption of folate-rich food products
45
. The dietary folate intake of people from Northern China 270 
mainly depends on their consumption of grains, while folate-rich food products, such as (green) 271 
vegetables, are the main folate sources in Southern China
17
. With respect to Han populations, the 272 
most common ethnicity in China, regional differences could be also due to the higher frequency of 273 
mutation in the MTHFR (5-methyl-tetrahydrofolate reductase) gene of Han people from Northern 274 
China
12
.  275 
Furthermore, Chinese men tend to be more folate deficient than women. Folate deficiency 276 
rates of males are approximately 2 to 5 times higher in Northern and Southern China, respectively.  277 
As the total folate deficiency rates are derived from two Chinese studies, the estimation of 278 
the number of folate deficient people in China should be interpreted carefully. Nevertheless, the 279 
findings show that folate deficiency in Northern China is a major health problem. 280 
 281 
Table 1 Folate deficiency in China. Percentage of folate deficient men and women (of childbearing age), and the 282 
estimated population affected by folate deficiency in China, per region  283 
 284 
Region Folate deficiency rate (%) 
                          
Population
c
 
(million) 
 Men
a Womena CBAb Totala Total 
NORTH 51.5 24.1 20.0 38.0 211.4 
Northeast / / 22.8 / / 
Northwest / / 14.5 / / 
SOUTH 11.0 1.9 1.5 6.2 47.4 
Southeast / / 1.0 / / 
Southwest / / 2.0 / / 
CHINA
d
 28.1 13.3 9.3 19.6 258.8 
 285 
CBA, women of childbearing age 286 
a 
Own calculations, based on Hao et al45 287 
b 
Based on Zhao et al17  288 
c 
Own calculations, based on the total folate deficiency rate (column 5) and the total population size (see Table 3) 289 
d 
Own calculations, means are weighted by population size (see Table 3) 290 
 291 
Folate deficiency is of particular importance in one of the northern provinces in China, 292 
namely Shanxi Province. Together with the Balrampur District in India
51
, this poor coal mining 293 
region has one of the highest NTD prevalence rates in the world (between 60 and 150 NTDs per 294 
10,000 births
8, 9, 52, 53
, up to an NTD rate of 199
7
). This high incidence is correlated with the high 295 
folate deficiency rates of pregnant women (43.8 %)
12
 and the limited use of folic acid pills (see 296 
section 5.1.1.) in this region
10-13
. 297 
 298 
2.3. Folate deficiency compared with other micronutritional deficiencies in China 299 
 300 
China, one of the largest countries in the world, is not only affected by folate deficiency.  301 
Table 2 summarizes the key indicators of folate deficiency and other micronutrient deficiencies 302 
(iron, vitamin A, iodine and zinc) in China. Although these indicators differ according to the type of 303 
micronutrient deficiency, this table provides an insight into the magnitude of micronutrient 304 
malnutrition in China.  305 
Vitamin A deficiency, for instance, remains a serious health problem in Chinese preschool 306 
children (11.4 million) and mothers (396 million), especially those living in rural areas
54
. The 307 
average share of Vitamin A deficient preschool children varies between 12.2 %
55
 and 16.0 %
56
, of 308 
which 30,500 children die from increased susceptibility to infection
56
.  309 
With respect to zinc deficiency, a study of Ma et al
29
 estimated the total number of Chinese 310 
zinc deficient people to be around 86 million. 311 
Another important type of micronutrient deficiency is iron deficiency. The number of people 312 
affected by iron deficiency anemia (IDA), 208.6 million, is a reliable indicator of the importance of 313 
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iron deficiency in China
29
. The high IDA prevalence rate of women of childbearing age (21 %) 314 
demonstrates that China‟s fight against iron deficiency is still going on54, 56.  315 
In comparison with important iodine deficient countries, the goitre (theroid swelling) rate in 316 
China - the main cause of iodine deficiency - is rather low. Nevertheless, more than 425 million 317 
people in China live in areas of endemic iodine deficiency
54
.Iodine deficiency in pregnancy, for 318 
instance, is responsible for the annual birth of nearly 2 million Chinese babies with intellectual 319 
impairment
56
.  320 
Although there is a lack of folate deficiency indicators in China, besides the NTD 321 
prevalence rate (12.9 NTDs per 10,000 births
9
), the high prevalence rate of folate deficiency from 322 
the study of Hao et al
45
 shows that folate deficiency is also an important micronutrient deficiency.  323 
 324 
Table 2 Estimations of the main micronutritional deficiencies in China  325 
 326 
 
Vitamin A 
deficiency 
Zinc 
deficiency 
Iron 
deficiency 
Iodine 
deficiency 
Folate 
deficiency 
Estimated affected 
population 
(million) 
 
11.4
a
 
(< 6 years)
 
396.4
a
 
(maternal) 
 
86.0
d
 
 
208.6
d
 
 
425
e
 
(living in ID areas) 
1,9
c
  
(children born  
mentally impaired) 
 
258.8
f
 
Prevalence rate of 
micronutrient 
deficiency 
indicators 
VAD 
12.2 %
b
 
16.0 %
c
  
(< 6 years)  
 
IDA 
8 % (< 5 years)
c
 
21 % (CBA)
b
 
Goitre rate 
10
c 
 
 
NTD 
12.9 NTDs  
per 
10,000 births
g 
 327 
CBA, women of childbearing age; VAD, Vitamin A deficiency; IDA, iron deficiency anemia; ID, Iodine deficiency; NTD, neural-tube defects  328 
a 
Based on the 5th UN Report on the World Nutrition Situation57 329 
b 
Based on a Chinese study of Jingxiong et al55  330 
c 
Based on a report of UNICEF and The Micronutrient Initiative56 331 
d 
Based on a Chinese study of Ma et al29 332 
e 
Based on a Chinese review of Shi-an et al54 333 
f 
Own calculations, see Table 1 334 
g 
Based on Dai et al9 see Table 3 335 
 336 
 337 
3. Neural-tube defects 338 
 339 
Neural-tube defects, the main adverse health outcome of folate deficiency, are characterized 340 
by malformations of the spine (such as spina bifida), skull or brain (eg. anencephaly; 341 
encephalocele), and are considered to be the most common congenital malformations in the world
58
. 342 
These malformations occur when the open neural tube, formed in the early stages in the 343 
development of the human embryo, fails to close around the 28th day after fertilization. As a 344 
consequence, the development of skull and/or spine is hampered.  345 
The relationship between maternal folate deficiency and the risk of having a baby with an 346 
NTD is widely established in scientific literature (for a review, see Lumley et al
5
). Worldwide, 347 
studies explored the impact of periconceptional folate intake on the prevalence of NTDs
3, 59-61
. 348 
Given that folate deficiency refers to a daily folate intake below 400 µg, between 50 % and 70 % of 349 
all NTDs in the world are considered to be attributable to folate deficiency. These global protective 350 
rates are understood as the percentage of NTDs that can be prevented by consuming the daily 351 
recommended folate level of 400 µg. 352 
 353 
 354 
 355 
 356 
 357 
 358 
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3.1. Neural-tube defects in the world 359 
 360 
Folate deficiency leads to an annual number between 200,000 and 300,000 neural-tube 361 
defects
62-64
 and is responsible for 1 out of 10 adult deaths from heart diseases
63
. Like all birth 362 
defects, NTDs are considered a global health problem, but almost all severe or fatal defects occur in 363 
developing, low-income countries
62
. Nevertheless, neural-tube defects are still present in the 364 
Western world
40
. Every year more than 4,500 births in the European Union are affected by neural 365 
tube defects
65
. In the United States the prevalence rates for the two most common NTDs, spina 366 
bifida and anencephaly, were 1.8 per 10,000 live births and 1.1 per 10,000 live births, 367 
respectively
66
. The lower prevalence of NTDs in the United States, about 3,000 per year, is partly 368 
based on the successful implementation of policy interventions to increase folate intake (see section 369 
5.1.2.). 370 
Figure 4 gives an overview of the top 20 countries according to the estimated annual number 371 
of neural-tube defects. The number of NTDs is considered as an important indicator of the 372 
magnitude of folate deficiency. There is a significant difference in the estimated number of NTDs 373 
between the two highest ranked countries, India and China, and the other countries. Inadequate 374 
folate intake levels in China are causing approximately 18,000 NTDs each year. These NTDs 375 
account for one-third of stillbirths and a quarter to a third of neonatal deaths, mainly due to the high 376 
prevalence of NTDs in Northern China
8, 9
(see section 3.2.).  When controlled for population size, 377 
African and Middle-Eastern countries are the most problematic (For a global report on birth defects 378 
and NTDs, see Christianson et al
62
 and the UNICEF Global Damage Assessment Report
63
, 379 
respectively ). 380 
 381 
 382 
 3
Figure 4 The estimated annual number of neural-tube defects, Top 20 countries.  384 
Source: Own calculations based on UNICEF
63
, Busby et al
65
 (EU), Cherian et al
51
 (India) and Table 4 (China) 385 
 
386 
3.2. Neural-tube defects in China 387 
 388 
Given China‟s position in the world ranking of neural-tube defects (see Figure 4), this 389 
section further explores the number of neural-tube defects in China and its regions (For a map of the 390 
administrative areas/regions, see Annex 1, Figure 6). Table 3 presents the most relevant 391 
demographic statistics to calculate the total number of NTDs according to its main type (spina 392 
bifida, anencephaly or encephalocele). In 2007, China is characterized by a total population of 1.3 393 
billion people and, based on a birth rate of 11.2 births per 1,000 population, approximately 14 394 
million births. As no recent regional life expectancy rates are available, the life expectancy of these 395 
births, 71.24 years for China, refers to the year 2000
67
. The NTD prevalence rates per 396 
administrative area and region are expressed per 10,000 births and refer to NTD affected 397 
pregnancies within the period 1996 to 2000
9
. Therefore, these rates are used as approximate 398 
incidence rates. In Figure 7 of Annex 1, a graphical presentation of the NTD prevalence rates per 399 
administrative region is shown.   400 
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Table 3 Demographic profile of China, total population, birth rate, total births and life expectancy at birth, and NTD 401 
prevalence rates per functional outcome, per administrative area and region 402 
 403 
Region/ 
Administrative 
area 
Population
a
  Births  NTD rate
d
 
Total 
Rate
b
 
 Life (per 10,000 births) 
(x 1,000 persons) Total expectancy
c
 Anenc. Spina  Enceph. Total 
NORTH 556,299 10.8 6,028,946 73.19 7.3 10.2 2.4 19.9 
Northeast 458,688 10.4 4,761,446 73.59 6.6 10.3 2.3 19.2 
Beijing  16,171 8.3 134,544 76.10 2.3 5.8 1.4 9.6 
Tianjin  10,996 7.9 86,975 74.91 3.7 10.3 2.2 16.2 
Hebei  70,557 13.3 940,520 72.54 5.1 9.2 2.6 16.9 
Shanxi  34,521 11.3 390,089 71.65 27.2 27.2 6.6 60.9 
Inner Mongolia  24,518 10.2 250,327 69.87 17.0 11.8 3.2 32.0 
Liaoning  43,686 6.9 300,993 73.34 4.3 11.0 1.6 16.9 
Jilin  27,852 7.6 210,284 73.10 5.0 8.2 0.9 14.0 
Heilongjiang 39,103 7.9 308,134 72.37 4.6 5.2 1.3 11.1 
Shandong  95,218 11.1 1,057,870 78.14 1.6 6.8 1.3 9.7 
Henan  96,067 11.3 1,081,711 73.91 5.1 12.4 3.3 20.8 
Northwest 97,611 13.0 1,267,500 72.39 9.4 9.9 2.9 22.2 
Shaanxi  38,203 10.2 390,056 74.70 12.3 14.5 5.8 32.6 
Gansu  26,656 13.1 350,254 71.85 11.7 12.2 2.6 26.5 
Qinghai 5,606 14.9 83,691 72.55 6.6 6.6 2.0 15.3 
Ningxia  6,178 14.8 91,431 68.95 9.2 10.1 1.8 21.1 
Xinjiang  20,969 16.8 352,068 73.92 5.9 4.8 2.5 13.3 
SOUTH 764,524 11.4 8,741,811 69.42 2.7 2.2 0.8 5.8 
Southeast 565,087 11.5 6,524,892 69.96 2.7 2.1 0.8 5.6 
Shanghai  18,564 9.1 168,380 71.54 0.7 0.8 0.4 1.8 
Jiangsu 77,226 9.4 723,603 71.08 1.5 2.0 0.4 3.9 
Zhejiang 50,938 10.4 528,734 70.66 2.6 2.8 0.3 5.7 
Anhui 62,497 12.8 796,833 73.27 5.3 4.0 1.6 10.8 
Fujian  36,393 11.9 433,081 71.29 4.3 1.5 1.2 6.9 
Jiangxi  44,383 13.9 615,153 72.92 2.2 2.5 1.1 5.8 
Hubei  58,231 9.2 535,144 71.73 2.9 2.0 1.3 6.2 
Hunan 64,869 12.0 775,832 71.20 2.6 3.8 1.1 7.4 
Guangdong  95,166 12.0 1,138,180 65.96 2.5 2.1 1.0 5.6 
Guangxi  48,269 14.2 684,936 65.49 5.1 0.7 0.5 6.2 
Hainan  8,551 14.6 125,017 64.37 2.7 1.0 0.2 3.9 
Southwest 199,437 11.1 2,216,919 68.23 2.8 2.7 1.0 6.6 
Sichuan  83,557 9.2 769,557 70.07 1.8 1.5 1.1 4.4 
Guizhou  38,430 13.3 510,350 67.47 4.3 6.9 0.7 11.9 
Yunnan  45,854 13.1 599,776 66.03 1.8 1.0 1.0 3.8 
Tibet 2,874 16.4 47,141 70.17 3.6 3.6 0.0 7.3 
Chongqing  28,722 10.1 290,094 67.41 4.0 2.0 1.6 7.6 
CHINA 1,320,823 11.2 14,770,757 71.24 5.0 6.3 1.6 12.9 
a
 Population figures of 2007 are based on the China Statistical Yearbook 200867 404 
b
 Birth rates are expressed per 1,000 population in 2007, based on the China Statistical Yearbook 200867 405 
c
 Regional life expectancy at birth in 2000 is expressed in years, based on the China Statistical Yearbook 200867 406 
d
 NTD prevalence rates between 1996 – 2000 are expressed per 10,000 births, based on a study of Dai et al9.  407 
 408 
 409 
Based on the population, the birth rate and the NTD prevalence rate (Table 3), the total 410 
number of NTDs can be calculated for each administrative area (Table 4). To define the number of 411 
NTDs per functional outcome, reference is made to the composition of NTDs in the study of Li et 412 
al
8
, where NTDs were ascertained from live births, still births and induced abortions in Shanxi 413 
Province. While abortions are considered as a voluntary or spontaneous termination of a pregnancy, 414 
stillbirths are defined as births of a baby with no signs of life
68
. According to this Chinese study,   415 
31 % of all NTDs are considered to be abortions, and live births and stillbirths account for 40.09 % 416 
and 28.91 % of all NTDs, respectively. These figures are in line with other studies in China
52, 69
. 417 
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Within the group of NTD live births, the number of cases of spina bifida and encephalocele is 418 
determined by the proportion of their prevalence rate and the total NTD prevalence rate. 419 
 420 
Table 4 Neural-tube defects in China, per functional outcome, per administrative area and region 421 
 422 
Region/  
Administrative  
area 
Non-Fatal Fatal    Total 
   Spina Enceph. Total   Abort.  Stillb. Total  
NORTH 3,957 1,031 4,988 3,857 3,597 7,454 12,443 
Northeast 3,057 734 3,791 2,932 2,734 5,666 9,457 
Beijing  41 10 52 40 37 77 129 
Tianjin  47 10 56 44 41 84 141 
Hebei  499 140 639 494 461 955 1,594 
Shanxi  767 185 952 736 687 1 423 2,375 
Inner Mongolia  253 68 321 248 231 479 800 
Liaoning  178 26 204 158 147 305 509 
Jilin  107 11 118 92 85 177 295 
Heilongjiang 110 27 137 106 99 205 343 
Shandong  345 65 410 317 295 612 1,022 
Henan  711 191 902 697 650 1,347 2,249 
Northwest 900 298 1,197 926 863 1,789 2,986 
Shaanxi  365 145 509 394 367 761 1,270 
Gansu  307 65 372 287 268 556 927 
Qinghai 39 12 51 40 37 77 128 
Ningxia  66 12 77 60 56 115 193 
Xinjiang  123 64 187 145 135 280 467 
SOUTH 1,584 651 2,236 1,729 1,612 3,341 5,577 
Southeast 1,176 488 1,664 1,287 1,200 2,486 4,150 
Shanghai  8 4 12 10 9 18 31 
Jiangsu 96 17 113 87 82 169 282 
Zhejiang 108 13 121 94 87 181 302 
Anhui 248 97 345 267 249 516 861 
Fujian  67 53 120 93 87 180 300 
Jiangxi  99 44 143 111 103 214 357 
Hubei  81 51 132 102 95 198 330 
Hunan 180 50 231 178 166 345 575 
Guangdong  170 85 255 197 184 381 636 
Guangxi  103 68 171 132 123 256 427 
Hainan  16 3 19 15 14 29 49 
Southwest 409 163 572 442 413 855 1,427 
Sichuan  80 56 136 105 98 203 338 
Guizhou  220 24 244 189 176 365 609 
Yunnan  45 45 90 70 65 135 225 
Tibet 14 0 14 11 10 21 34 
Chongqing  50 39 88 68 64 132 220 
CHINA 5,541 1,683 7,224 5,586 5,210 10,796 18,020 
 423 
Each year, a total of 18,020 pregnancies are affected with an NTD in China, most of them 424 
with a fatal result. It is important to notice that the total NTD figures in Table 2 refer to all NTDs, 425 
i.e. NTDs caused by folate deficiency or other factors, such as genetic or environmental
70
, except 426 
for spontaneous NTD related abortions. Although there is evidence on the positive relationship 427 
between a history of spontaneous abortions and an increased prevalence of NTDs
71
, the number of 428 
spontaneous NTD related abortions are not investigated in this study. If information on the number 429 
of NTDs that result in a spontaneous termination would be available, the number of NTDs in China 430 
would be higher.  431 
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When comparing Chinese regions, the NTD prevalence rate is more appropriate as an 432 
indicator of NTD-risk regions than the total number of NTDs. Although Shanxi Province, situated 433 
in the Northeast, obtains the highest NTD prevalence rate (60.9), Northwest China is considered as 434 
the most problematic Chinese region, with 22.2 NTDs per 10,000 births. The significant difference 435 
between Northern and Southern China is shown in both the NTD rate and the total number of NTD 436 
(see also Annex 1, Figure 7). While 31 % of all NTD affected pregnancies occur in Southern China, 437 
in its northern counterpart accounts for more than two thirds of all Chinese NTDs.  438 
 439 
3.3. Neural-tube defects caused by folate deficiency in China 440 
 441 
Although the total number of NTDs has been used as an indicator of the importance of folate 442 
deficiency (see section 3.1.), only a part of these NTDs are attributable to folate deficiency. This 443 
section estimates the number of neural-tube defects caused by folate deficiency in China. As there is 444 
a lack of data on the contribution of folate deficiency to other functional outcomes, NTDs caused by 445 
folate deficiency are the only functional outcomes of folate deficiency that will be included in the 446 
DALY framework to measure the current burden of folate deficiency (see section 4) and the health 447 
impact of folate biofortification (see section 6). This implies an underestimation of the global health 448 
benefits of folate biofortified rice. Its health impact would be significantly higher when other 449 
outcomes of folate deficiency could be included, such as megaloblastic anemia, heart diseases and 450 
cancer. Nevertheless, as NTDs are not only considered as the main adverse health outcome of folate 451 
deficiency, but also as the world‟s major congenital malformation, the number of NTDs is a 452 
valuable indicator to measure the current burden of folate deficiency.  453 
As there is currently no data on the contribution of folate deficiency to NTDs in each 454 
administrative area, two regional contribution levels are used to determine the number of NTDs 455 
caused by folate deficiency. Based on a folic acid supplementation study among pregnant women 456 
(see section 5.1.1.), Berry et al
72
 estimated that women in Northern and Southern China are able to 457 
reduce the risk of having a baby with an NTD by 85 % and 40 %, respectively, if they achieve the 458 
daily folate recommendation of 400 µg. In other words, respectively 85 % and 40 % of all NTDs 459 
are attributable to folate deficiency in northern and southern regions. Although this study only 460 
investigated some of the provinces in Northern and Southern China, similar protective rates are 461 
found in a Chinese study of Chen et al
73
.    462 
Based on these regional contribution levels and the total number of NTDs in Table 4, the 463 
number of NTDs caused by folate deficiency are calculated in Table 5. The use of different 464 
contribution levels in Northern and Southern China explains the increased regional difference in the 465 
number of NTDs caused by folate deficiency. No less than 83 % of all these NTD affected 466 
pregnancies in China occur in the north, and in particular, in the northwest. Even more striking is 467 
the number of the NTDs in Shanxi Province, which is almost as high as the whole southern part.  468 
With respect to the different functional outcomes, almost 60 % of the NTDs has a fatal 469 
outcome. If the NTD results in a live birth, malformations in the back (i.e. spina bifida) are the most 470 
frequent outcome. When linking Table 5 to the input parameters of the DALY framework (see 471 
section 4.2.), the total number of non-fatal and fatal NTDs caused by folate deficiency are 472 
considered as the combined input parameters TjIij and TjMj, respectively. 473 
474 
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Table 5 Neural-tube defects caused by folate deficiency in China, per functional outcome, per administrative area and 475 
region 476 
 477 
Region/  
Administrative  
area 
Non-Fatal Fatal    Total 
   Spina Enceph. Total   Abort. Stillb. Total  
NORTH 3,363 877 4,240 3,279 3,058 6,336 10,576 
Northeast 2,599 624 3,223 2,492 2,324 4,816 8,038 
Beijing  35 9 44 34 32 66 110 
Tianjin  40 8 48 37 35 72 120 
Hebei  424 119 543 420 392 812 1,355 
Shanxi  652 158 809 626 584 1,209 2,019 
Inner Mongolia  215 58 273 211 197 407 680 
Liaoning  151 22 173 134 125 259 433 
Jilin  91 9 101 78 73 150 251 
Heilongjiang 93 23 117 90 84 175 291 
Shandong  293 55 348 269 251 520 868 
Henan  604 162 766 593 553 1,145 1,912 
Northwest 765 253 1,018 787 734 1,521 2,538 
Shaanxi  310 123 433 335 312 647 1,080 
Gansu  261 55 316 244 228 472 788 
Qinghai 33 10 44 34 32 65 109 
Ningxia  56 10 66 51 47 98 164 
Xinjiang  105 55 159 123 115 238 397 
SOUTH 634 261 894 692 645 1,337 2,231 
Southeast 470 195 666 515 480 995 1,660 
Shanghai  3 2 5 4 4 7 12 
Jiangsu 38 7 45 35 33 68 113 
Zhejiang 43 5 48 37 35 72 121 
Anhui 99 39 138 107 100 206 345 
Fujian  27 21 48 37 35 72 120 
Jiangxi  40 18 57 44 41 85 143 
Hubei  32 21 53 41 38 79 132 
Hunan 72 20 92 71 67 138 230 
Guangdong  68 34 102 79 74 152 255 
Guangxi  41 27 68 53 49 102 171 
Hainan  6 1 8 6 6 12 19 
Southwest 163 65 229 177 165 342 571 
Sichuan  32 22 54 42 39 81 135 
Guizhou  88 10 98 75 70 146 243 
Yunnan  18 18 36 28 26 54 90 
Tibet 6 0 6 4 4 8 14 
Chongqing  20 15 35 27 25 53 88 
CHINA 3,997 1,137 5,134 3,970 3,703 7,673 12,807 
 478 
Note: These figures are determined by the total number of NTDs (Table 2) and the contribution level of folate deficiency to NTDs in Northern (85 %) 479 
and Southern China (40 %). 480 
 481 
  482 
Nature Biotechnology, vol. 28, no. 6 DeSteur, H. et al.
15 
 
4. Current burden of folate deficiency in China 483 
 484 
4.1. The DALY formula 485 
 486 
The Disability-Adjusted Life Year method is used to quantify the burden of folate deficiency 487 
as a single index, i.e. the number of DALYs lost. This number equals the sum of the “Years Lived 488 
with Disability” (YLD) and “Years of Life Lost” (YLL), which represent, respectively, disability-489 
weighted morbidity and cause-specific mortality due to folate deficiency. The DALY formula
23, 26
 490 
to estimate both the death and disease condition resulting from folate deficiency is expressed as:  491 
  492 
The input parameters of the formula are the total number of people in target group j (Tj); the 493 
mortality rate associated with the deficiency in target group j (Mj); incidence rate of functional 494 
outcome i in target group j (Iij); the disability weight for functional outcome i in target group j, (Dij); 495 
the duration of functional outcome i in target group j (dij); the average remaining life expectancy for 496 
target group j (Lj) and the discount rate for future life years (r).  497 
When applying this formula to calculate the burden of folate deficiency, only NTDs caused 498 
by folate deficiency are included as functional outcomes. Therefore, the three main NTD types, i.e. 499 
spina bifida, encephalocele (also known as cranium bifidum) and anencephaly, in particular those 500 
NTDs that are attributable to folate deficiency, are considered as functional outcomes in this study. 501 
The target groups referring to these NTDs are births, both fatal and non-fatal, as these are the ones 502 
that will be directly influenced by their mother‟s biofortified diet. The functional outcomes related 503 
to these target groups are split up into a non-fatal (morbidity) and fatal (mortality) component. 504 
While the latter is determined by abortions and stillbirths, the former consists of live births suffering 505 
from spina bifida or encephalocele. The third NTD type, anencephaly, results in death before or 506 
shortly after birth and is considered as a part of the mortality component
74, 75
. The values of the 507 
input parameters of the DALY framework are further described in section 4.2. 508 
 509 
4.2. Input parameters of the DALY formula 510 
 511 
Table 6 summarizes all input parameters that are included in the DALY formula. The input 512 
parameters TjIij and TjMj are presented in Table 5 and refer to non-fatal and fatal functional 513 
outcomes, respectively. Disability weights of the functional outcomes (Dij) differ according to the 514 
level of severity or disability, and range from 0 („healthy‟) to 1 („death‟)18. The average remaining 515 
life expectancy (Lj) of stillbirths and abortions refers to the average life expectancy at birth (see 516 
Table 3). Also the duration of a non-fatal NTD (dij) is assumed to be permanent, by which dij equals 517 
Lj. Based on the global burden of disease study of Mathers et al
75
, a disability weight of 0.593 and 518 
0.52 is attributed to spina bifida and encephalocele, respectively. The discount rate for future life 519 
years (r) amounts to 3 percent, in accordance with previous health impact studies
23, 26
. 520 
 521 
Table 6 Overview of the input parameters of the DALY formula, applied to China  522 
 523 
Functional outcome TjIij TjMj Dij Lj=dij r 
Morbidity      
Spina bifida Table 5, column 2 NA 0.593 
Table 3, column 5  3 % 
Encephalocele Table 5, column 3 NA 0.520 
Mortality      
Stillbirths NA Table 5, column 5 NA 
Table 3, column 5  3 % 
Abortions NA Table 5, column 6 NA 
 524 
Tj, total number of people in target group j; Iij, incidence rate of functional outcome i in target group j; Mj, the mortality rate associated with the 525 
deficiency in target group j; Dij, the disability weight for functional outcome i in target group j; Lj, the average remaining life expectancy for target 526 
group j; dij, the duration of functional outcome i in target group j; r, discount rate for future life years; NA, not applicable 527 
 528 
4.3. The current burden of folate deficiency in China (DALYs lost) 529 
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 530 
The present burden of folate deficiency in China, i.e. the situation „without‟ biofortification, 531 
can be calculated by entering the input parameters of Table 6 into the DALY formula. This burden 532 
is expressed in the number of DALYs lost per administrative area (Table 7). Based on the present 533 
consumption pattern, folate deficiency in China is responsible for an annual loss of 314,180 534 
DALYs. With respect to the regional differences, the number of DALYs lost is significantly higher 535 
in Northern China, especially in the northeast. However, when these numbers are weighted 536 
according to the total population, the current situation is worst in Northwest China, with 6.39 537 
DALYs lost per 10,000 persons, per year (see also Table 11, column 3). By way of comparison, the 538 
annual number of DALYs lost in the northeast is 4.31 per 10,000 persons. The relative burden in 539 
Southern China is significantly lower with 0.71 DALYs lost per 10,000 persons. These findings are 540 
mainly a consequence of differences in NTD prevalence rates and the regional contribution level of 541 
folate deficiency to NTDs. Regarding the functional outcomes, the burden of morbidity and 542 
mortality caused by folate deficiency amounts to 27.85 % and 72.15 %, respectively. Within these 543 
categories, spina bifida obtains the highest number of years lived with disability, while the lost life 544 
years are more or less equally divided between the two fatal outcomes. 545 
546 
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Table 7 Burden of folate deficiency in China, per functional outcome, expressed in the number of DALYs lost, per 547 
year, per region and administrative area 548 
 549 
Region/ 
Administrative 
area 
Non-Fatal Fatal Total 
Spina Enceph. Total (YLD) Abortions 
   
Stillbirths Total (YLL)  
NORTH 59,067 13,502 72,569 97,100 90,554 187,654 260,223 
Northeast 45,642 9,600 55,242 73,791 68,816 142,608 197,849 
Beijing  623 137 760 1,016 948 1,964 2,724 
Tianjin  702 129  831 1,107 1,032 2,139 2,970 
Hebei  7,429 1,832 9,261 12,411 11,574 23,986 33,246 
Shanxi  11,381 2,414 13,794 18,429 17,187 35,616 49,411 
Inner Mongolia  3,725 879 4,604 6,165 5,749 11,913 16,517 
Liaoning  2,660 341 3,001 3,976 3,708 7,684 10,685 
Jilin  1,601 146 1,747 2,305 2,150 4,455 6,202 
Heilongjiang 1,637 359 1,995 2,668 2,488 5,155 7,151 
Shandong  5,239 861 6,100 8,112 7,565 15,677 21,777 
Henan  10,645 2,502 13,148 17,602 16,415 34,018 47,165 
Northwest 13,425 3,902 17,327 23,309 21,737 45,046 62,374 
Shaanxi  5,473 1,907 7,380 9,972 9,300 19,272 26,652 
Gansu  4,560 845 5,404 7,202 6,716 13,918 19,323 
Qinghai  586 158 744  999 931 1,930 2,674 
Ningxia  963 150 1,113 1,479 1,379 2,858 3,971 
Xinjiang  1,843 843 2,686 3,657 3,411 7,068 9,754 
SOUTH 10,978 3,954 14,931 20,194 18,832 39,026 53,957 
Southeast 8,169 2,968 11,137 15,066 14,050 29,115 40,252 
Shanghai  57 25 82 112 104  216  299 
Jiangsu 667 106 773 1,028 958 1,986 2,759 
Zhejiang 753 79 832 1,099 1,025 2,125 2,957 
Anhui 1,742 600 2,343 3,165 2,951 6,116 8,459 
Fujian  466 327 793 1,094 1,021 2,115 2,908 
Jiangxi  695 271 966 1,309 1,221 2,529 3,495 
Hubei  565 315 880 1,205 1,124 2,329 3,209 
Hunan 1,257 309 1,565 2,098 1,956 4,054 5,619 
Guangdong  1,159 508 1,667 2,266 2,114 4,380 6,047 
Guangxi  698 408 1,107 1,518 1,415 2,933 4,040 
Hainan  110 19 129 172  160  332  461 
Southwest 2,809 985 3,794 5,128 4,783 9,911 13,705 
Sichuan  554 340  894 1,228 1,145 2,373 3,267 
Guizhou  1,511 143 1,654 2,184 2,036 4,220 5,874 
Yunnan  308 270 578  803 749 1,553 2,131 
Tibet 96 0 96  125 116  241 337 
Chongqing  340 232 572  789  736 1,524 2,097 
CHINA 70,044 17,456 87,500 117,294 109,386 226,680 314,180 
  550 
DALYs, Disability-Adjusted Life Years; YLD, years lived in disability; YLL, years of life lost 551 
 552 
 553 
  554 
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5. Policy interventions to tackle folate deficiency 555 
 556 
Like other micronutrient deficiencies, folate deficiency can be addressed by four strategies: 557 
distributing folic acid supplements (pharmaceutical supplementation), fortifying foods with folic 558 
acid (industrial fortification), diversifying people‟s diets to increase the consumption of folate-rich 559 
foods (dietary diversification) or enhancing the folate content of staple crops (biofortification). 560 
While the former two interventions aim to limit folate deficiency through the increased intake of 561 
synthetic folic acid, the objective of the latter two strategies is to enhance the natural folate intake 562 
level. Folic acid based interventions are often criticized because of the relationship between 563 
excessive folic acid intake and masking anemia caused by vitamin B12 deficiency
76
. Although the 564 
folic acid fortification policy in the United States did not cause a major increase in the number of 565 
vitamin B12 deficient people
38
, and a multi-micronutrient fortification policy to increase both folic 566 
acid and vitamin B12 could be a partial solution for the future
41, 76
, the debate about the adverse 567 
health effects of high folic acid intake hampers the introduction of mandatory folic acid fortification 568 
in many (European) countries
77
. 569 
The following sections briefly discuss the different policy interventions to tackle folate 570 
deficiency in relation to the (Chinese) policy context (For a general overview and comparison of the 571 
different interventions to tackle nutritional deficiencies, we refer to the Stein et al
25
). As not all 572 
interventions have been implemented in China, the experience of folate or other nutritional 573 
programs in other countries is also drawn.  574 
 575 
5.1. Folic acid based interventions 576 
 577 
5.1.1. Folic acid supplementation  578 
   579 
Folic acid supplementation is an external nutritional intervention to tackle folate deficiency 580 
in specific target groups by promoting the use of folic acid or multivitamin supplements. 581 
Supplementation programs mainly target women of childbearing age. By encouraging them to 582 
consume daily folic acid pills from the periconceptional period until approximately three months of 583 
gestation, the number of NTDs can be reduced. The ability to focus on specific population groups is 584 
considered as both an advantage and disadvantage of this intervention. On the one hand, targeting 585 
women of childbearing age tackles folate deficiency where it is most needed. On the other hand, a 586 
population-based approach is needed, as folate deficiency is present in all sections of the 587 
population
42
. 588 
Folic acid pills generally contain 400 µg of folic acid, which is in line with the folate 589 
recommendations. Therefore, a daily consumption of such pills is currently considered as the most 590 
effective strategy for women of childbearing age in order to prevent them against a pregnancy 591 
affected by an NTD caused by folate deficiency (for a review of the relationship between folic acid 592 
supplementation and NTDs, see Lumley et al
5
). Besides these daily supplements, folic acid can also 593 
be given less frequently, e.g. 5 mg on a weekly basis. Although weekly supplementation could be a 594 
practical answer to the low compliance to consume folic acid supplements, evidence is needed to 595 
demonstrate that it is as effective as daily folic acid supplements
78
.  596 
Folic acid supplements can also be delivered with other micronutrients. By implementing 597 
such a multivitamin program, by which folic acid is incorporated in another vitamin supplement, 598 
such as vitamin A capsules, duplication of costs and efforts can be avoided. 599 
 600 
Supplementation programs  601 
 602 
Effective supplementation programs were introduced in Philippines, Cambodia, and 603 
Vietnam, where pregnant women received free daily iron and folic acid supplements and non-604 
pregnant women were encouraged to take weekly supplements
79
. In Western and Northern Europe, 605 
folic acid supplementation policies are well established, but their effectiveness to reduce NTDs is 606 
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rather limited
40, 65, 76
. The success of supplementation programs depends on the duration and the 607 
intensity of supplementation efforts, the accessibility of supplements, the effectiveness of the health 608 
system and the inclusion of a targeted educational component in the program
78, 80
. However, 609 
pharmaceutical supplementation is not considered as a long-term solution to tackle folate 610 
deficiency. Previous campaigns to promote folic acid supplementation in the United States
81
 and 611 
The Netherlands
82
, for instance, increased knowledge about folic acid, but were less effective in 612 
stimulating the use of folic acid supplements. And if a program is effective, the increased folic acid 613 
intake is often not sustainable and decreases again once the program ceased
83
 (For a review of the 614 
success of folic acid supplementation programs, see Cordero et al
78
). 615 
 616 
China and supplementation 617 
 618 
Because of the one child per family policy, the prevention and control of birth defects is a 619 
high priority for the Chinese government. In their “2002-2010 National Action Plan for Reducing 620 
Birth Defects and Disabilities in China”, the Ministry of Health (MOH) and the Chinese Disabled 621 
Person Federation (CDPF) recommend that all women of child-bearing age should obtain folic acid 622 
and health information on folic acid supplementation, in order to bring birth defects under effective 623 
control by 2010
84
. By the end of 2010, at least 60% of all married women who plan to be pregnant 624 
have to achieve the daily recommendation for folate. Therefore, a national public health education 625 
campaign and a national preconception care program is released. In 2009, for instance, about 12 626 
million rural Chinese women of child-bearing age received free folic acid supplements
85
. 627 
Although such supplementation programs are expected to reduce the number of NTDs, the 628 
reduction is likely to be a short term effect. Between 1993 and 1995 for instance, a successful folic 629 
acid supplementation intervention was conducted as a part of the public health campaign
72
.  This 630 
intervention reduced the number of NTDs by delivering folic acid supplements to women during 631 
their mandatory premarital health examination. However, once the program ceased, the NTD 632 
prevalence rate increased to its pre-supplementation value
86
.  633 
Despite previous supplementation efforts, the current intake of folic acid supplements is 634 
very low in rural areas and high risk regions. In Shanxi Province, for example, only 10 % of women 635 
of childbearing age once used folic acid pills, regardless of their knowledge about the correct time 636 
of use
10, 11
. The low compliance of taking folic acid supplements in such poor, rural areas might be 637 
determined by the price of folic acid (30 pills of 400 µg folic acid is about 10 yuan or 1.5 dollar) 638 
and the limited access
86
. Low compliance of taking folic acid supplements is also a consequence of 639 
the large number of unintended pregnancies in China. Most Chinese women are not aware of the 640 
need to take folic acid supplements during the periconceptual period. Therefore, implementing a 641 
targeted folic acid supplementation program will be more difficult when all women of childbearing 642 
age need to be reached and continuation of the program is crucial to keep them motivated
78
. 643 
  644 
5.1.2. Folic acid fortification  645 
 646 
While folic acid supplementation targets a specific population group, (industrial) folic acid 647 
fortification, i.e. adding folic acid directly to staple crops during the first stage of milling, is 648 
currently considered as the most effective population-based strategy to fight folate deficiency 649 
without altering dietary habits
41
. As successful folic acid fortification requires specialized 650 
infrastructure, strict quality control and strong partnerships between public and private sectors, folic 651 
acid fortification is less feasible in developing countries and regions that are characterized by large 652 
micronutrient deficiencies
78, 80, 87
. In line with the multivitamin strategy, folic acid can be added to 653 
existing fortified foods, which is successfully demonstrated in Costa Rica
88
. 654 
 655 
 656 
 657 
 658 
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Fortification programs  659 
 660 
In 2005, about 38 countries had opted for a mandatory folic acid fortification policy
76
. In the 661 
United States
34, 89
 and Canada
60
, for example, cereal grain products were fortified with folic acid to 662 
a level of 140 and 150 μg per 100 g, respectively. Other countries focused their mandatory folic 663 
acid fortification policy on one (e.g. wheat flour in Chile
90
) or more food vehicles (e.g. wheat flour, 664 
corn flour, milk and rice in Costa Rica
88
). In general, these mandatory fortification programs led to 665 
increased folic acid consumption levels
78
. As a consequence, the folate intake requirements for most 666 
adults were met or exceeded, and the number of NTDs decreased, e.g. from 4,000 to 3,000 NTD 667 
affected pregnancies in the United States
91
. In Europe, most countries have voluntarily folic acid 668 
fortified foods and in some cases, such as in Ireland and in the UK, the introduction of mandatory 669 
folic acid fortification has been advocated
40, 76, 92
. Only Eastern Europe and Eurasia currently 670 
embrace mandatory folic acid fortification. Kazakhstan, for example, is in the process of 671 
implementing the laws to require a certain level of folic acid in flour (Flour Fortification Initiative; 672 
http://www.sph.emory.edu/wheatflour/). 673 
 674 
China and fortification 675 
 676 
In 2003, the flour fortification pilot program “Flour Fortification in the Western Region of 677 
China” was initiated by the State Grain Bureau and the Ministry of Health in China93, 94. With the 678 
support of the Global Alliance for Improved Nutrition (GAIN), a market-based, voluntary 679 
fortification program was introduced, with a folic acid fortification level of 200 μg per 100 g. This 680 
resulted in the production of fortified flour, often known as “7+1 flour”, in a few companies. 681 
However, due to delays in implementation, this project came to an end in 2008. 682 
Between 2006 and 2007, folic acid fortified flour was introduced to more than 60,000 683 
consumers in the high NTD risk region of Shanxi Province, as a part of the “Strong Newborn” 684 
project
93
. The objective of this program was to evaluate the effect of flour fortification in the 685 
prevention of NTDs. Although the findings indicate a positive effect, there were significant 686 
problems to guarantee the quality of fortified flour and to obtain funding in order to start a 687 
province-wide implementation. 688 
In 2008, the Chinese Public Nutrition and Development Center (PNDC) developed a 689 
voluntary flour fortification standard, which was released by the State Grain Authority (SGA)
93, 95
. 690 
However, at present, very little flour is voluntary fortified in China (about 1 %)
93
. Given the limited 691 
access to voluntary folic acid fortified foods in China, the main challenge will be to guarantee that 692 
the fortified food vehicle will actually (continue to) reach the Chinese consumer, especially in the 693 
rural regions of China. As policy makers have still concerns on the feasibility of folic acid 694 
fortification in China, the Chinese Ministry of Health intend to undertake additional flour and rice 695 
fortification trials in the future
86, 93
. Nevertheless, the actual implementation of provincial flour 696 
fortification in the market will depend largely on provincial authorities‟ interest and commitment. 697 
 698 
5.2. Folate based interventions 699 
 700 
5.2.1. Dietary diversification  701 
 702 
Dietary diversification aims to modify the dietary patterns of consumers through 703 
interventions that promote the consumption of micronutrient-rich foods, e.g. home gardening, as 704 
well as nutrition education, e.g. learning consumers to retain micronutrients during processing. 705 
Previous food-based strategies focused mainly on the reduction of Vitamin A or iron deficiencies 706 
(for a review, see Ruel
96
). Although this strategy is considered to be the most sustainable solution, 707 
there are currently no scientific reports of population-based interventions which promoted a folate-708 
rich diet (e.g. green leafy vegetables and orange-fleshed fruits)
78
. While a vegetarian eating pattern, 709 
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characterized by long-term high consumption of vegetables, positively affects the folate intake
97
, 710 
dietary folate interventions are not necessarily effective to address folate deficiency
98
. 711 
Furthermore, such food-based strategies rely on food varieties that are already available in 712 
the market. Due to the limited availability and consumption of folate-rich products in Northern 713 
China, it will be difficult to modify the eating behaviors in this high NTD risk region
17, 45
. 714 
Especially in the poor rural areas, where consumers mainly consume folate-poor staple crops, such 715 
as rice, increasing the consumption of folate-rich food products is less feasible than pro-poor 716 
interventions, such as folate biofortification (see section 5.2.2.). 717 
 718 
5.2.2. Folate biofortification  719 
 720 
Biofortification is a pro-poor and pro-rural strategy that uses plant breeding techniques, such 721 
as conventional breeding or transgenic techniques, to develop staple food crops for higher 722 
micronutrient content
99
. The first example of a genetically engineered biofortified staple crop is rice 723 
enriched with beta-carotene to tackle Vitamin A deficiency, also known as Golden Rice
100
.  724 
Folate biofortification, the enhancement of folate in staple food crops, can improve the 725 
folate intake of malnourished rural populations that are unlikely to benefit from folic acid 726 
fortification or supplementation. Currently, rice with a high folate content, developed by metabolic 727 
engineering, is the most advanced folate biofortified staple crop
33, 101, 102
. Storozhenko et al
1
 728 
obtained different transgenic lines with a folate content ranging from 350 to 1,700 µg per 100 g of 729 
raw polished grains. These figures are 20 to 100 times higher than normal folate levels in rice
103
. 730 
Even though there is a clear potential to use conventional plant breeding techniques to increase the 731 
folate content of rice (e.g. conventional biofortification of other vitamins in maize, wheat, beans, 732 
cassava, and rice
104
), it may be hard to reach the same level of enhancement as in transgenic 733 
techniques, because of the low intrinsic folate concentrations in natural rice varieties
102, 105
 (For a 734 
detailed discussion on the technological issues regarding folate biofortification of food plants and 735 
rice, see Storozhenko et al
1
 and Bekaert et al 
102
, respectively). 736 
As such, folate biofortification of rice, the world‟s main staple crop, can be considered as an 737 
alternative and complementary approach to the above mentioned strategies, especially in regions 738 
where other interventions are less successful or feasible. First of all, unlike folic acid fortification or 739 
supplementation, folate biofortification does not rely on industrial food processing, specialized 740 
distribution channels or accessible health systems. Second, it is considered to be a more sustainable 741 
approach due to the possibility of re-sowing the biofortified seeds from the previous harvest. Third, 742 
possible negative side effects of folic acid fortification, such as masking Vitamin B12 deficiency and 743 
the increased risk of colorectal cancer, are less likely to occur with folate biofortification (see 744 
section 2). 745 
 However, in comparison with the targeted approach of folic acid supplementation, there is 746 
no assurance that the population will achieve to consume the recommended amount of folate. 747 
Furthermore, folate in food is subject to additional losses due to the processing methods, such as 748 
cooking
106
, and its bioavailability degree (50 %) is significantly lower than in folic acid fortified 749 
foods or supplements, respectively 85 % and 100 %
107, 108
. Moreover, biofortification, initially 750 
applied to improve the micronutritional content of staple crops, may alter other attributes, such as 751 
appearance and taste. Such negative attributes may limit consumer acceptance and, in turn, reduce 752 
the potential impact of this intervention. Consumers in Kenya
109
 and Mozambique
110
, for instance, 753 
preferred traditional white maize over yellow-orange biofortified maize, which is enriched with 754 
provitamin A. In the latter study, the authors even found a negative consumer perception of the 755 
flavor of biofortified maize. Although folate biofortification is not expected to change sensory and 756 
visual product attributes
102
, similar to folic acid fortification
111
, further research is needed to 757 
determine the influence of folate biofortification on product attributes and its consumer acceptance.  758 
 759 
 760 
 761 
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China and biofortification 762 
 763 
China is considered as one of the world leaders in the field of R&D and commercialization 764 
of genetically modified foods. Research on biofortification of staple crops became increasingly 765 
important for China‟s food security policy, especially after China‟s entry into the World Trade 766 
Organization (WTO) in 2001
80, 112
. The HarvestPlus China Program, for example, initiated in 2004 767 
eight research projects related to the development of biofortified maize, wheat, sweet potato and 768 
rice in China, in order to address specific micronutrient deficiencies, such as Fe or Vitamin A
113
 769 
(http://www.harvestplus-china.org/). Nevertheless, no transgenic crop was approved for animal or 770 
human consumption until recently, when China‟s Ministry of Agriculture (MOA) granted two bio-771 
safety certificates and approved phytase maize (feed crop) and biotech Bt rice (food crop)
16
. The 772 
permission to cultivate these major transgenic crops is expected to lead to full commercialization in 773 
about two to three years. As a consequence, China will be the first to introduce a troika of key 774 
transgenic crops into the market place, i.e. Bt cotton (fiber), phytase maize (feed) and Bt rice 775 
(food)
114
. The approval and deployment of the latter will probably lead to the approval of other 776 
transgenic food crops, including biofortified staple crops. 777 
Even though this might be promising for biofortified staple crops, including folate enriched 778 
rice, the process and outcome of the standard food safety and environmental field trials makes it 779 
impossible to predict if and when these biotech crops will be approved in China. Furthermore, if 780 
(transgenic) biofortified crops will be introduced, labeling of transgenic food crops will probably be 781 
required, as outlined by the Chinese State Council
80
. With respect to the Chinese Intellectual 782 
Property Rights (IPR), patent registration and enforcement probably need to be reformed and 783 
centralized in order to improve IPR-protection for biofortified crops (for more information on 784 
biofortification policy issues in China, we refer to Campos-Bower et al
80
 and Pray et al 
112
). 785 
 Although the approval of BT rice might be a catalyst of approving biofortified staple crops, 786 
there is a clear difference between these two types of transgenic crops. While the former 787 
encompasses improvements of agronomic traits, i.e. insect resistance, the latter improves quality 788 
traits, such as a higher folate content
115
. From a policy point of view it can be argued that GM crops 789 
that are attractive to both farmers (e.g. by increasing yields due to the improved crop quality; 1
st
 790 
generation crops) and consumers (e.g. by improving health due to the enhanced nutritional quality; 791 
2
nd
 generation crops), will increase public acceptance, and thus, gain political acceptance. The 792 
combination of a nutritional and an agronomic trait in staple food crops is considered to be more 793 
than the sum of parts. Besides its potential for cost-reduction through the combined implementation 794 
efforts, these crops improve farmer‟s health directly, through consumption, and indirectly, through 795 
promoting sustainable agriculture (increased yields, productivity and income)
116
. Together with 796 
multi-biofortification, where one staple crop is enriched with a full range of nutrients, among which 797 
folate, this strategy should be put as a priority on the research agenda. Targeting different 798 
micronutrient deficiencies at once is a strategy which is also found in other policy interventions, 799 
such as pharmaceutical supplementation (e.g. multivitamin supplements), food fortification (e.g. 800 
multi-micronutrient fortification, including folic acid and Vitamin B12) and dietary diversification, 801 
if it aims to tackle malnutrition as a whole by improve dietary habits.  Golden Rice, for example, is 802 
assumed to be cost-effective, as shown in scientific literature (see for instance, Stein, et al
25
). 803 
Crossing our folate trait into this biofortified crop would be an interesting approach to tackle folate 804 
and Vitamin A deficiencies and to improve the health impact by introducing one multi-biofortified 805 
crop. However, combining first and second generation GM crops, such as Bt rice with a high folate 806 
content, would definitely go further by providing an economic incentive to farmers. 807 
This paper focuses on the world‟s most consumed staple crop, rice, as the food vehicle for 808 
folate biofortification. China is one of the key players in terms of producing and consuming rice, as 809 
well as GM rice
14, 15
. While Japonica rice is the dominant rice variety in Northern China, Indica rice 810 
is mainly planted in Southern China. With respect to folate biofortified rice in China, it will be 811 
important to cross folate biofortified rice into local varieties to reach the poorest consumers in the 812 
rural regions. In addition, to ensure that Chinese farmers will produce this variety, the trait needs to 813 
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be crossed into a variety that has a high yielding potential, such as Bt rice, and the product should 814 
be incorporated into existing marketing chains
102
. The success of introducing folate biofortified rice 815 
further depends on the efficacy of systems to disseminate such improved rice varieties. 816 
 817 
 818 
6. The health impact of folate biofortified rice in China 819 
 820 
The health impact of the introduction of folate enriched rice depends on different factors, as 821 
Figure 5 depicts. Two important determinants are directly related to folate enriched rice, namely its 822 
efficacy (section 6.1.) and coverage rate (section 6.2.). While the former determines the folate dose, 823 
the latter defines the market potential of this crop and, thus, the response to this dose. Information 824 
about the current folate intake levels and the current rice consumption patterns is used to calculate 825 
the total folate intake after biofortification, which reduces the number of maternal folate 826 
deficiencies and, thus, reduces the number of neural-tube defects, i.e. the response or the health 827 
benefits.  828 
This framework to assess the health benefits of folate biofortified rice is based upon 829 
previous health impact studies
26, 99
. Because the health impact is related to the number of NTDs in 830 
China, two target groups are considered. On the one hand, newborns are considered as the target 831 
group of the health benefits, as they carry the risk of having a neural-tube defect. On the other hand, 832 
due to the relationship between maternal folate deficiency and the risk of delivering a baby with an 833 
NTD, women of childbearing age are the target group for folate biofortified rice consumption. The 834 
calculation method and the assumptions for each determinant are described in the next two sections. 835 
The health impact of introducing folate biofortified rice in China is presented in section 6.3 and 836 
compared with other health impact studies in section 6.4. 837 
 838 
 839 
 840 
 841 
 842 
 843 
 844 
 845 
 846 
 847 
 848 
 849 
 850 
 851 
Figure 5 The health impact of folate biofortified rice 852 
Remarks:  Efficacy = (folate content in rice, µg per 100 g)*(% folate retention, %)*(degree of bio-availability, %)  853 
Additional folate intake = (efficacy, µg per 100 g) - (initial folate content of 100 g rice)  854 
 Coverage rate = (maternal acceptance rate, %)*(„access‟ = farmers‟ acceptance rate, %)  855 
Total folate intake after biofortification = (current folate intake, µg) + (additional folate intake, µg per g)*(rice consumption, g) 856 
 857 
6.1. Total folate intake after folate biofortification of rice in China 858 
 859 
The efficacy of folate biofortified rice is calculated by multiplying the amount of additional 860 
folate in rice with the retention of folate after processing the rice and its bioavailability. For the 861 
calculations in this paper we have used 1,200 µg per 100 g raw polished grains. This folate content 862 
will be reduced by 50 % during rice processing, i.e. cooking
1
. To take into account the 863 
bioavailability upon ingestion, this folate retention will be reduced by 50 %
107, 108
. Combining these 864 
three efficacy parameters results in a total folate intake of biofortified rice of 300 µg per 100 g rice. 865 
Given the initial folate content of rice, 8 µg per 100 g
35
, the total added folate intake amounts 292 866 
µg per 100 g. 867 
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Given that the current rice patterns do not differ after introducing folate biofortified rice, the 868 
total folate intake of Chinese women of childbearing age after biofortification can be estimated by 869 
adding the additional folate intake to the current folate intake (Table 8). The average daily rice 870 
consumption can be calculated for each administrative area, based on data from the China‟s 871 
National Grain and Oils Information Center
117
. The lack of regional rice consumption data for 872 
women of childbearing age is an important limitation of this study. The maternal intake of rice 873 
could be lower than the average, which could influence the total folate intake after biofortification 874 
and, thus, the success of the intervention. Although most of the administrative areas have high 875 
folate intake levels after biofortification, this could be a problem in, for instance, Shandong and 876 
Xinjiang. However, this can be tackled by implementing a transgenic line with a higher folate 877 
content, such as 1,700 µg per 100 g of raw polished grains (see section 5.2.1.). 878 
Rice consumption in Southern China is twice as large as in Northern China. On average, a 879 
Chinese person consumes 315.29 g of rice per day. Also the current daily folate intake is higher in 880 
Southern China (212.9 µg per woman of childbearing age) than in Northern China (188.0 µg per 881 
woman of childbearing age). This is in accordance with a study of Dexter
118
 which found a higher 882 
prevalence of micronutrient deficiencies in rice consuming regions. A geographical presentation of 883 
this relationship is included in Annex 1, where rice consumption (Figure 8), rice production   884 
(Figure 9) and folate intake after biofortification (Figure 10) in China are juxtaposed.  885 
Given the current rice consumption, the current folate intake and the additional folate intake 886 
of biofortified rice, a scenario where Chinese women completely switch to folate biofortified rice 887 
and do not alter their rice consumption pattern results in an average folate intake of 1,120.41 µg per 888 
day, per woman of childbearing age. This is almost three times the required intake or 280 % of the 889 
recommended daily intake (RDI). Regional folate intake levels after biofortification vary from 890 
552.18 µg, per day, per person in Shandong (northeast) to 1,941.66 µg, per day, per person in 891 
Hunan (southeast). The contribution of the total folate intake after biofortification to the 892 
recommended dose varies between 136.29 % in Xinjiang (northwest) and 485.41 % in Hunan 893 
(southeast). Although rice consumption and folate intake in the northern regions are significantly 894 
lower, the required daily folate intake can still be achieved if folate biofortified rice is consumed.   895 
When reporting folate levels above 1,000 µg, doubts about the risk of masking Vitamin B12 896 
deficiency can be raised
102, 106, 107
 (see also section 2). Vitamin B12 deficiency is characterized by 897 
macrocytic anemia and neurological impairment. The diagnosis of Vitamin B12 may be delayed by 898 
folic acid (reduction to H4folate), as the latter can correct the macrocytosis. However, as our folate 899 
biofortified rice mainly contains 5-methyl-tetrahydrofolate (MTHF), the effect of masking this 900 
micronutrient deficiency is absent
1
. This is because the synthesis of H4folate from 5-MTHF is 901 
catalyzed by a Vitamin B12 dependent enzyme (methionine synthase). Therefore, a functional folate 902 
deficiency occurs when Vitamin B12 is lacking, which makes an early diagnosis of Vitamin B12 903 
deficiency possible
36
. Furthermore, in regions with folate intake levels higher than 1,000 µg after 904 
folate biofortification, such as in Southern China (except Tibet), a transgenic line with a lower 905 
folate content can be deployed to avoid negative side effects associated with high folate intake 906 
levels.  907 
 908 
  909 
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Table 8 Folate biofortification of rice in China in an optimal scenario (100 % consumption of biofortified rice). Current 910 
rice and folate consumption,  added and total folate intake after biofortification, and % of RDI, per administrative area 911 
and region 912 
 913 
 914 
Region/  
Administrative area 
Current  Added Total  
rice cons.
a
 folate intake
b
 folate intake
c
 folate intake
d
 % of RDI
e
 
g /day/person µg /day/CBA µg /day/CBA µg /day/CBA  
NORTH 181.14 188.0 528.92 716.92 179.23 
Northeast 186.48 190.9 544.51 735.41 183.85 
Beijing  379.50 190.9 1,108.15 1,299.05 324.76 
Tianjin  286.54 190.9 836.70 1,027.60 256.90 
Hebei  134.35 190.9 392.31 583.21 145.80 
Shanxi  157.14 190.9 458.85 649.75 162.44 
Inner Mongolia  166.50 190.9 486.18 677.08 169.27 
Liaoning  279.71 190.9 816.75 1,007.65 251.91 
Jilin  321.66 190.9 939.24 1,130.14 282.54 
Heilongjiang 294.27 190.9 859.26 1,050.16 262.54 
Shandong  123.73 190.9 361.28 552.18 138.04 
Henan  133.18 190.9 388.90 579.80 144.95 
Northwest 156.06 182.7 455.69 638.39 159.60 
Shaanxi  159.21 182.7 464.88 647.58 161.90 
Gansu  153.15 182.7 447.19 629.89 157.47 
Qinghai 161.29 182.7 470.96 653.66 163.42 
Ningxia  252.78 182.7 738.13 920.83 230.21 
Xinjiang  124.12 182.7 362.44 545.14 136.29 
SOUTH 412.90 212.9 1,205.66 1,418.56 354.64 
Southeast 435.53 215.1 1,271.73 1,486.83 371.71 
Shanghai  360.09 215.1 1,051.47 1,266.57 316.64 
Jiangsu 390.25 215.1 1,139.52 1,354.62 338.65 
Zhejiang 493.75 215.1 1,441.76 1,656.86 414.21 
Anhui 284.95 215.1 832.04 1,047.14 261.79 
Fujian  484.06 215.1 1,413.45 1,628.55 407.14 
Jiangxi  520.37 215.1 1,519.49 1,734.59 433.65 
Hubei  394.74 215.1 1,152.65 1,367.75 341.94 
Hunan 591.29 215.1 1,726.56 1,941.66 485.41 
Guangdong  358.42 215.1 1,046.60 1,261.70 315.42 
Guangxi  575.54 215.1 1,680.59 1,895.69 473.92 
Hainan  278.74 215.1 813.93 1,029.03 257.26 
Southwest 348.79 210.4 1,018.46 1,228.86 307.22 
Sichuan  357.40 210.4 1,043.60 1,254.00 313.50 
Guizhou  300.85 210.4 878.48 1,088.88 272.22 
Yunnan  307.11 210.4 896.75 1,107.15 276.79 
Tibet 142.97 210.4 417.47 627.87 156.97 
Chongqing  475.03 210.4 1,387.08 1,597.48 399.37 
CHINA 315.29 199.8 920.64 1,120.41 280.10 
CBA, woman of childbearing age; RDI, the recommended daily intake (i.e. folate) 915 
a 
The daily rice consumption per person is expressed per person, in 2007119. 916 
b 
The current, regional folate intake before biofortification refers to findings from Zhao et al17. 917 
c 
The total added folate intake due to biofortification is based on the total current rice intake (column 1), folate intake (column 2) and additional folate 918 
content of biofortified rice, 2.92 µg per g.  919 
d 
Sum of the current and additional folate intake. 920 
e 
Calculated by comparing the total folate intake after biofortification with the recommended daily intake (RDI) of folate, i.e. a daily average folate 921 
intake of 400 µg folate per person. 922 
 923 
 924 
 925 
 926 
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6.2. Assumptions to measure the health impact of folate biofortified rice in China 927 
 928 
In order to assess the health impact of folate biofortification, assumptions have to be made 929 
with respect to the effect of additionally absorbed folate on folate deficiency, the so-called “dose-930 
response”. The “dose” is understood as the average daily folate intake after biofortification in China 931 
and its regions (see Table 8, column 5). Although a few studies investigated the effect of different 932 
folate doses on the reduction of NTD incidence
59, 61
, there is still a lack of scientific evidence to 933 
measure the health impact of each of the regional total folate intake levels in China. To overcome 934 
this problem, the “response” is evaluated by comparing the total folate intake level of women of 935 
childbearing age in each of the Chinese administrative areas with the recommended folate intake 936 
(see Table 8, column 6). In accordance to previous literature, the “response” to a daily folate intake 937 
of 400 µg or higher is understood as the prevention of folate deficiency and its adverse health 938 
outcomes, e.g. NTDs
2, 5
. Given that each administrative area in China exceeds the recommended 939 
daily folate intake of 400 µg per childbearing woman, consumption of folate biofortified rice with 940 
an initial folate content of approximately 1,200 µg per 100 g rice is assumed to prevent maternal 941 
folate deficiency and the risk of having a baby affected with an NTD caused by folate deficiency. 942 
The use of average, regional folate intake levels in the dose-response relationship is an important 943 
limitation, which may bias the results. Therefore, it is important to notice that it is the average 944 
women of childbearing age that can recover from folate deficiency through a biofortified diet. 945 
Nevertheless, a regional comparison of average folate intake levels with the recommended folate 946 
dose is also a valuable approach, as the effectiveness of biofortification as a strategy to combat 947 
folate deficiency in all Chinese administrative areas can be evaluated.  948 
Because only women who agree to consume the folate biofortified rice will recover from 949 
folate deficiency and its health risks, the dose after biofortification only refers to a part of the 950 
market. This part is determined by the coverage rate, which combines women‟s acceptance of and 951 
their access to farmers willing to produce folate enriched rice. According to a recent Chinese study
6
, 952 
55.4 % of female rice consumers are willing to accept rice with a high folate content, while 32.3 % 953 
react indifferent and 12.3 % are reluctant. The findings for farmers are even more positive, with 954 
66.7 % accepting and only 6.6 % of the farmers rejecting the rice. Although this study was 955 
conducted in Shanxi Province, the results are in line with other Chinese consumer studies on other 956 
GM food products
120-123
. Therefore, by combining acceptance and access to farmers, a low and high 957 
coverage rate are defined. While the former (36.95 %) contains only accepting female consumers 958 
which have access to approving farmers, the high coverage rate (81.91 %) also takes into account 959 
females and farmers that are indifferent to folate biofortified rice. These coverage rates are defined 960 
as the percentage of women that switch completely to folate biofortified rice, compared to women 961 
that hold on to traditional rice. In that way, they determine the percentage of women that can 962 
recover from folate deficiency by a biofortified diet. It is important to notice that it will depend on 963 
policy decisions regarding labeling and the availability of, and access to folate biofortified rice, and 964 
its product characteristics, such as visual and sensory attributes, whether women will actually be 965 
able and willing to switch completely to folate biofortified rice, instead of consuming a mix of rice 966 
varieties. Assuming such a mix may lead to a lower health impact of folate biofortification 967 
compared to the health benefits of a complete switch to folate biofortified rice.  968 
 969 
6.3. The health impact of folate biofortification of rice in China (DALYs saved)  970 
 971 
Based on the product and market characteristics of folate biofortified rice, described in the 972 
previous sections, the benefits to public health can be assessed by comparing the number of DALYs 973 
lost under the current situation (“without”) with two biofortification scenario‟s (“with”). A low and 974 
high impact scenario are defined by the coverage rate of folate biofortified rice, i.e. 36.95 % (low) 975 
and 81.91 % (high) of Chinese women who are willing to accept and have access to this crop. These 976 
scenarios start from the assumption that the total folate intake under biofortification in each 977 
administrative area in China is significantly higher than the threshold to prevent folate deficiency 978 
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and the risk of delivering a baby affected with an NTD (see Table 8). Table 9 and Table 10 979 
summarize the health benefits of folate biofortification of rice in China under a low and high impact 980 
scenario, respectively. The results are expressed as the number of DALYs saved through the 981 
implementation of folate enriched rice. It is the difference between the number of DALYs lost 982 
under the current situation, shown in Table 7, and the DALYs lost under a folate biofortification 983 
scenario. This health impact, expressed in DALYs saved, refers to the number of children with an 984 
NTD that are “saved”, which is based on the number of their mothers that recover from folate 985 
deficiency through a biofortified diet, i.e. the coverage rate. Since some of the parameters of the 986 
DALY framework are based on different years (i.e. NTD prevalence rate in 2004, rice consumption 987 
in 2007, coverage rate in 2008), this annual number of DALYs gained through biofortification has 988 
to be perceived as a theoretical number, rather than a real figure. 989 
The potential introduction of folate biofortified rice in China increases the folate intake for 990 
women of childbearing age to 1,120 µg per day, and saves annually 116,090 DALYs in the low and 991 
257,345 DALYs in the high biofortification scenario. Regarding the functional outcomes, fatal 992 
outcomes gain the largest number of DALYs, followed by spina bifida and encephalocele. While 993 
the burden in the low biofortification scenario is still around 200,000 DALYs per year, the high 994 
impact scenario reduces the annual number of DALYs lost to approximately 57,000. In other words, 995 
63.05 % and 18.09 % of all NTDs caused by folate deficiency are still present after folate 996 
biofortification in the low and high impact scenario, respectively. This is equal to the percentage of 997 
women who did not switch to folate biofortified rice and, therefore, did not recovered from folate 998 
deficiency. When focusing on the four Chinese regions, the highest number of DALYs saved is 999 
obtained in Northeast China. Shanxi Province, characterized by one of the highest NTD prevalence 1000 
rates in the world, benefits the most from the introduction of folate biofortified rice. The health 1001 
impact in the northwest, southwest and southeast of China is significantly lower.  1002 
According to the target group, newborns or their mothers, the health impact can be 1003 
interpreted in two ways. First, the health benefits can be expressed in terms of DALYs saved, based 1004 
on the reduced number of births affected with an NTD, due to their mothers biofortified diet. 1005 
Second, based on the coverage rate of folate biofortified rice, the health impact can also be 1006 
understood as the number of women of childbearing age, including mothers, recovering from folate 1007 
deficiency. This “double” health impact is an important argument to underpin future 1008 
communication strategies in order to tackle folate deficiency and its adverse health outcomes. 1009 
  1010 
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Table 9 The health impact of folate biofortification of rice in China, low impact scenario, per functional outcome, 1011 
expressed in the number of DALYs saved, per year, per region and administrative area 1012 
 1013 
Region/ 
Administrative 
area 
Non-Fatal Fatal Total 
Spina Enceph. Total (YLD) Abortions 
   
Stillbirths Total (YLL)  
NORTH 21,825 4,989 26,814 35,879 33,460 69,338 96,152 
Northeast 16,865 3,547 20,412 27,266 25,428 52,694 73,105 
Beijing  230 51 281 375 350 726 1,007 
Tianjin  259 48 307 409 381 791 1,098 
Hebei  2,745 677 3,422 4,586 4,277 8,863 12,285 
Shanxi  4,205 892 5,097 6,810 6,351 13,160 18,257 
Inner Mongolia  1,376 325 1,701 2,278 2,124 4,402 6,103 
Liaoning  983 126 1,109 1,469 1,370 2,839 3,948 
Jilin  592 54  646  852 794 1,646 2,292 
Heilongjiang 605 133 737 986 919 1,905 2,642 
Shandong  1,936 318 2,254 2,997 2,795 5,793 8,047 
Henan  3,933 925 4,858 6,504 6,066 12,570 17,428 
Northwest 4,960 1,442 6,402 8,613 8,032 16,645 23,047 
Shaanxi  2,022 705 2,727 3,685 3,436 7,121 9,848 
Gansu  1,685 312 1,997 2,661 2,482 5,143 7,140 
Qinghai 216 58 275  369 344 713 988 
Ningxia  356 55 411 546 510 1,056 1,467 
Xinjiang  681 312 993 1,351 1,260 2,612 3,604 
SOUTH 4,056 1,461 5,517 7,462 6,959 14,420 19,937 
Southeast 3,018 1,097 4,115 5,567 5,191 10,758 14,873 
Shanghai  21 9 30 41 39 80  110 
Jiangsu 246 39 286 380 354 734 1,020 
Zhejiang 278 29 307 406 379 785 1,093 
Anhui 644 222 866 1,169 1,091 2,260 3,126 
Fujian  172 121 293 404 377 781 1,075 
Jiangxi  257 100 357 484 451 935 1,291 
Hubei  209 116 325 445 415 861 1,186 
Hunan 464 114 578 775 723 1,498 2,076 
Guangdong  428 188 616 837 781 1,618 2,234 
Guangxi  258 151 409 561 523 1,084 1,493 
Hainan  41 7 48 63 59 123  170 
Southwest 1,038 364 1,402 1,895 1,767 3,662 5,064 
Sichuan  205 126 330 454 423  877 1,207 
Guizhou  558 53 611 807 752 1,559 2,171 
Yunnan  114 100 214 297 277 574 787 
Tibet 35 0 35 46 43 89 124 
Chongqing  126 86 211 291 272 563 775 
CHINA 25,881 6,450 32,331 43,340 40,418 83,758 116,090 
 1014 
DALYs, Disability-Adjusted Life Years; YLD, years lived in disability; YLL, years of life lost 1015 
Note: These figures are determined by a low coverage rate of folate biofortified rice, i.e. 36.95 %. The coverage rate is the percentage of women who 1016 
consume folate biofortified rice and recover from folate deficiency. It is also the percentage of NTDs caused by folate deficiency that can be 1017 
prevented by a mother‟s biofortified diet. 1018 
 1019 
1020 
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Table 10 The health impact of folate biofortification of rice in China, high impact scenario, per functional outcome, 1021 
expressed in the number of DALYs saved, per year, per region and administrative area 1022 
 1023 
Region/ 
Administrative 
area 
Non-Fatal Fatal Total 
Spina Enceph. Total (YLD) Abortions Stillbirths Total (YLL)  
NORTH 48,382 11,060 59,441 79,535 74,173 153,707 213,149 
Northeast 37,385 7,863 45,248 60,442 56,367 116,810 162,058 
Beijing  511 112 623 832  776 1,609 2,231 
Tianjin  575 105 681 907 846 1,752 2,433 
Hebei  6,085 1,501 7,585 10,166 9,481 19,647 27,232 
Shanxi  9,322 1,977 11,299 15,096 14,078 29,173 40,472 
Inner Mongolia  3,051 720 3,771 5,049 4,709 9,758 13,529 
Liaoning  2,179 279 2,458 3,257 3,037 6,294 8,752 
Jilin  1,311 120 1,431 1,888 1,761 3,649 5,080 
Heilongjiang 1,341 294 1,634 2,185 2,038 4,223 5,857 
Shandong  4,291 706 4,997 6,645 6,197 12,841 17,838 
Henan  8,720 2,050 10,769 14,418 13,446 27,864 38,633 
Northwest 10,996 3,197 14,193 19,092 17,805 36,897 51,090 
Shaanxi  4,483 1,562 6,045 8,168 7,618 15,786 21,831 
Gansu  3,735 692 4,427 5,899 5,501 11,401 15,827 
Qinghai 480 129 609 818  763 1,581 2,190 
Ningxia  789 123 912 1,211 1,130 2,341 3,252 
Xinjiang  1,510 691 2,200 2,996 2,794 5,789 7,989 
SOUTH 8,992 3,238 12,230 16,541 15,426 31,966 44,197 
Southeast 6,691 2,431 9,122 12,340 11,508 23,848 32,971 
Shanghai  47 21 67 92 86 177 245 
Jiangsu 546 87 633 842 785 1,627 2,260 
Zhejiang 617 65 681 901 840 1,740 2,422 
Anhui 1,427 492 1,919 2,592 2,417 5,010 6,929 
Fujian  382 268 650 896 836 1,732 2,382 
Jiangxi  569 222 791 1,072 1,000 2,072 2,863 
Hubei  463 258 721 987 921 1,908 2,628 
Hunan 1,029 253 1,282 1,718 1,602 3,321 4,603 
Guangdong  949 416 1,365 1,856 1,731 3,588 4,953 
Guangxi  572 334 906 1,243 1,159 2,402 3,309 
Hainan  90 16 106  141 131 272 377 
Southwest 2,301 807 3,108 4,201 3,917 8,118 11,226 
Sichuan  454 279 732 1,006 938 1,944 2,676 
Guizhou  1,238 117 1,355 1,789 1,668 3,456 4,812 
Yunnan  252 221  474 658 614 1,272 1,745 
Tibet 78 0 78 102 95 197  276 
Chongqing  279 190 469 646 603 1,249 1,717 
CHINA 57,373 14,298 71,671 96,076 89,598 185,674 257,345 
  1024 
DALYs, Disability-Adjusted Life Years; YLD, years lived in disability;YLL, years of life lost 1025 
Note: These figures are determined by a high coverage rate of folate biofortified rice, i.e. 81.91 %. The coverage rate is the percentage of women who 1026 
consume folate biofortified rice and recover from folate deficiency. It is also the percentage of NTDs caused by folate deficiency that can be 1027 
prevented by a mother‟s biofortified diet. 1028 
 1029 
1030 
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As the health benefits of folate biofortified rice depend on demographic characteristics, such 1031 
as population number and birth rate, a comparison of the regional results should be carefully 1032 
analyzed. One way to overcome this, is to standardize the regional saved DALYs (Table 11). When 1033 
the number of DALYs are expressed per 10,000 persons, the burden and health impact is relatively 1034 
the highest in the Northwest China, while the absolute numbers are the highest in the Northeast. The 1035 
current situation is most problematic in Shanxi (northeast), Gansu (northwest), Anhui (southeast) 1036 
and Guizhou (southwest). 1037 
 1038 
Table 11 Burden of folate deficiency (DALYs lost) and the health impact of folate biofortification (DALYs saved) in 1039 
China, expressed in the total number of DALYs and per 10,000 persons, per year, per region and administrative area  1040 
 1041 
Region/ 
Administrative 
area 
Current burden 
(DALYs lost) 
Folate biofortication  
(DALYs saved) 
  Low impact High impact 
Total 
  
Per 10,000 
persons  
Total 
  
Per 10,000 
persons 
Total  
 
Per 10,000 
persons  
NORTH 260,223 4.68 96,152 1.73 213,149 3.83 
Northeast 197,849 4.31 73,105 1.59 162,058 3.53 
Beijing  2,724 1.68 1,007 0.62 2,231 1.38 
Tianjin  2,970 2.70 1,098 1.00 2,433 2.21 
Hebei  33,246 4.71 12,285 1.74 27,232 3.86 
Shanxi  49,411 14.31 18,257 5.29 40,472 11.72 
Inner Mongolia  16,517 6.74 6,103 2.49 13,529 5.52 
Liaoning  10,685 2.45 3,948 0.90 8,752 2.00 
Jilin  6,202 2.23 2,292 0.82 5,080 1.82 
Heilongjiang 7,151 1.83 2,642 0.68 5,857 1.50 
Shandong  21,777 2.29 8,047 0.85 17,838 1.87 
Henan  47,165 4.91 17,428 1.81 38,633 4.02 
Northwest 62,374 6.39 23,047 2.36 51,090 5.23 
Shaanxi  26,652 6.98 9,848 2.58 21,831 5.71 
Gansu  19,323 7.25 7,140 2.68 15,827 5.94 
Qinghai 2,674 4.77 988 1.76 2,190 3.91 
Ningxia  3,971 6.43 1,467 2.37 3,252 5.26 
Xinjiang  9,754 4.65 3,604 1.72 7,989 3.81 
SOUTH 53,957 0.71 19,937 0.26 44,197 0.58 
Southeast 40,252 0.71 14,873 0.26 32,971 0.58 
Shanghai  299 0.16  110 0.06 245 0.13 
Jiangsu 2,759 0.36 1,020 0.13 2,260 0.29 
Zhejiang 2,957 0.58 1,093 0.21 2,422 0.48 
Anhui 8,459 1.35 3,126 0.50 6,929 1.11 
Fujian  2,908 0.80 1,075 0.30 2,382 0.65 
Jiangxi  3,495 0.79 1,291 0.29 2,863 0.65 
Hubei  3,209 0.55 1,186 0.20 2,628 0.45 
Hunan 5,619 0.87 2,076 0.32 4,603 0.71 
Guangdong  6,047 0.64 2,234 0.23 4,953 0.52 
Guangxi  4,040 0.84 1,493 0.31 3,309 0.69 
Hainan  461 0.54  170 0.20 377 0.44 
Southwest 13,705 0.69 5,064 0.25 11,226 0.56 
Sichuan  3,267 0.39 1,207 0.14 2,676 0.32 
Guizhou  5,874 1.53 2,171 0.56 4,812 1.25 
Yunnan  2,131 0.46 787 0.17 1,745 0.38 
Tibet  337 1.17 124 0.43  276 0.96 
Chongqing  2,097 0.73 775 0.27 1,717 0.60 
CHINA 314,180 2.38 116,090 0.88 257,345 1.95 
DALYs, Disability-Adjusted Life Years 1042 
  1043 
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6.4. Comparison of health impact studies with respect to biofortified staple crops  1044 
 1045 
By expressing the number of DALYs gained per 10 000 persons, the potential health impact 1046 
of folate biofortified rice in China can be compared with results from other health impact studies 1047 
that applied the DALY approach. Table 12 presents the estimated potential health impact of 1048 
introducing different transgenic and non-transgenic biofortified staple crops in several developing 1049 
countries.  1050 
In comparison with the burden of micronutrient deficiencies in other health impact studies, 1051 
the burden of folate deficiency in this study is relatively the lowest. However, as only NTDs caused 1052 
by folate deficiency are included as functional outcomes, only a part of this burden is calculated in 1053 
this study. If other functional outcomes would be included, such as heart diseases, the target group 1054 
would be extended to the total population. Given the estimated total number of folate deficient 1055 
people in China, 258 million, the actual burden of folate deficiency would be much higher.  1056 
With respect to the health impact, most of the DALYs are saved through the introduction of 1057 
Vitamin A biofortification in Uganda (sweet potato) and Congo (cassava roots). The relative impact 1058 
of iron or zinc biofortification on public health is the highest in India and Pakistan, and North-East 1059 
Brazil (iron) and Bangladesh (zinc). While the burden of our folate biofortified rice in China is 1060 
relatively low, this intervention obtains relatively one of the highest number of DALYs. This is 1061 
mainly due to the high folate intake levels after biofortification (see section 6.1.) and the 1062 
assumption that these intake levels prevent maternal folate deficiency and the risk of having a baby 1063 
with an NTD (see section 6.2).  1064 
Although this comparison is useful to place folate biofortification in the context of other 1065 
biofortified interventions to tackle micronutrient deficiencies in developing countries, these findings 1066 
should be interpreted with caution. First, the parameters of the DALY framework and the 1067 
characteristics of the impact scenarios differ from one study to another. Second, as there is currently 1068 
no biofortified staple crop commercialized, regardless of the technique that has been used, the 1069 
expected micronutrient content after biofortification is mostly based on estimates from plant 1070 
breeders. This is, for instance, the case in the HarvestPlus health impact analyses 1071 
(http://www.harvestplus.org) of Meenakshi et al
22
. 1072 
 1073 
 1074 
  1075 
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Table 12 Comparison of the burden of micronutrient deficiencies (DALYs lost) and the health impact of potential 1076 
biofortified staple crops (DALYs saved), per crop, nutrient, and country, in DALYs lost/saved per 10,000 persons and 1077 
in % reduction of the burden  1078 
 1079 
Crop  Nutrient Technique  Target country 
Burden of 
deficiencies 
Health impact  
      Pessimistic     Optimistic 
 Relative  % Relative    % 
Rice Vitamin A T India
b
 20.52 1.80 8.8 12.19 59.4 
   Philippines
c
 32.06 1.82 5.7 10.11 31.5 
 Iron C Bangladesh
a
  34.36 2.75 8.0 0.91 2.6 
   India
a
  35.27 1.76 5.0 7.22 20.5 
   India
e
 35.27 4.41 12.5 5.29 15.0 
   Philippines
a
  8.31 0.33 4.0 12.19 146.7 
 Zinc C Bangladesh
a
 30.86 5.25 17.0 10.18 33.0 
   India
a
  24.96 4.99 20.0 13.98 56.0 
   Philippines
a
  9.50 1.23 12.9 4.08 42.9 
 Folate T China
f
 2.38 0.88 37.0 1.95 81.9 
   Shanxi Province
f
 14.31 5.29 37.0 11.72 81.9 
Wheat Iron C India
e
 35.27 2.65 7.0 13.76 39.0 
  C India
a
 35.27 2.47 37.0 13.23 375.0 
   Pakistan
a
  57.65 3.46 7.5 8.82 15.3 
 Zinc C India
a
  24.96 2.25 6.0 11.98 48.0 
   Pakistan
a
  40.11 2.01 9.0 13.24 33.0 
Maize Vitamin A C Ethiopia
a
 52.76 0.53 5.0 8.97 17.0 
   Kenya
a
 32.27 2.58 1.0 10.33 32.0 
Cassava  
roots 
Vitamin A C Congo
a
 1206.93 36.21 8.0 386.22 32.0 
  Nigeria
d
 100.26 7.05 3.0 21.11 21.1 
  Nigeria
a
 57.14 1.71 7.0 16.00 28.0 
   North-East Brazil
a
 10.00 0.40 3.0 1.90 19.0 
Beans Iron C Honduras
a
  57.65 1.06 4.0 16.14 28.0 
   Nicaragua
a
 53.61 1.61 1.8 5.84 10.9 
   North-East Brazil
a
 40.00 3.60 3.0 8.58 21.5 
 Zinc C Honduras
a
  13.27 0.40 9.0 1.99 15.0 
   Nicaragua
a
  17.87 0.36 3.0 1.97 11.0 
   North-East Brazil
a
 20.00 1.00 2.0 4.00 20.0 
Sweet potato Vitamin A C Uganda
a
 56.64 21.52 5.0 36.25 64.0 
DALYs, Disability-Adjusted Life Years; T, biofortification using transgenic methods; C, biofortification using conventional methods 1080 
a 
Own calculations, based on Meenakshi et al22 1081 
b 
Own calculations, based on Stein et al25 1082 
c 
Own calculations, based on Zimmermann & Qaim26 1083 
d 
Own calculations, based on Manyong27 1084 
e 
Own calculations, based on Stein et al28 1085 
f 
These figures are based on Table 11, column 5 (burden), 7 (pessimistic) and 9 (optimistic) 1086 
 1087 
 1088 
7. Conclusions 1089 
 1090 
This paper evaluates the potential health benefits of a biofortified staple crop, namely rice 1091 
with a high folate content, in China. By means of  the Disability-Adjusted Life Years approach, the 1092 
health impact on folate deficiency is measured in terms of the number of DALYs lost. As China is 1093 
the world leader in rice consumption and production, and a key player in the research field of 1094 
genetically modification of rice, China was selected as the study location. Due to the specific 1095 
differences in terms of NTD prevalence, rice consumption and current folate intake, this health 1096 
impact analysis is conducted at regional and administrative divisional level.  1097 
Application of the DALY method reveals that the current burden of folate deficiency 1098 
amounts to an annual loss of 314,180 DALYs. The introduction of rice with a folate content of 1099 
1,200 µg per 100 g rice in China would save 116,090 DALYs in the low impact scenario and 1100 
257,345 DALYs in the high impact scenario. The burden and the health impact are the highest in 1101 
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Northern China, in absolute (northeast) as well as relative numbers (northwest). The region with the 1102 
highest NTD prevalence rate, Shanxi Province, will benefit the most from folate biofortification.  1103 
The regional health benefits in China are based on average daily folate intakes between    1104 
545 µg and 1,941 µg per woman of childbearing age, which are significantly higher than the 1105 
recommended folate intake of 400 µg. Although these numbers refer to averages, the high folate 1106 
intake level in China demonstrates that folate biofortification of rice can be a valuable means to 1107 
reduce folate deficiency and neural-tube defects. Especially in poor, rural regions where other folate 1108 
interventions are less feasible the introduction of folate enriched rice could be important. Even in 1109 
the northern regions, where wheat is more popular than rice, folate biofortification of rice could 1110 
contribute to achieve the recommended folate dose.  1111 
The DALY framework is a popular method to analyze the health impact of implementing 1112 
biofortified staple crops. As this is the first attempt to measure the health benefits of folate 1113 
biofortification, some recommendations can be made to further improve the research results. First, 1114 
collecting primary or fine tune secondary data would significantly benefit this health impact study. 1115 
While some parameters of the DALY framework have to be further explored (e.g. a stable folate 1116 
content of folate enriched rice and the exact degree of bioavailability), others need to be adapted 1117 
according to the study location (e.g. the current folate intake and the contribution level of folate 1118 
deficiency to NTDs, per administrative area) or the target group (e.g. rice consumption of women of 1119 
childbearing age). Second, to be able to calculate all health benefits of folate biofortified rice, 1120 
additional research is required to define the contribution of folate deficiency to each of its 1121 
functional outcomes.  1122 
However, before folate biofortified rice can be approved, it still needs to be figured out how 1123 
it will be introduced in China. The price, the availability, the accessibility and the dissemination of 1124 
folate biofortified rice, labeling and other legislation requirements, the selection of the transgenic 1125 
line and the rice variety (e.g. multi-biofortification) and product attributes will influence consumer 1126 
and farmer acceptance. Thus, public acceptance will be a crucial determinant of the approval and 1127 
the success of folate biofortified rice. Therefore, to further increase the health impact of folate 1128 
biofortified rice in China, once commercialization is approved, communication strategies should 1129 
focus on the coverage rate of folate biofortified rice. The higher the coverage rate, the more women 1130 
recover from folate deficiency, by which more NTDs will be prevented.  1131 
Building upon the investigated (regional) health impact, future research should focus on 1132 
analyzing the cost-effectiveness of folate biofortified rice in China. This can be done by juxtaposing 1133 
the costs of biofortification and the calculated health benefits. Another research topic is to involve 1134 
and compare different strategies to improve folate intake. As awareness and use of folic acid pills in 1135 
China is often low, especially in rural regions, and altering dietary habits is less feasible in poor, 1136 
rural regions, folate biofortified rice has to be considered as a complementary means to combat 1137 
folate deficiency. Although folate biofortification has particular advantages due to its pro-poor and 1138 
pro-rural approach, a combination of policy interventions will be probably the most feasible and 1139 
effective method to tackle folate deficiency in all sections of the population.  1140 
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